Estrogen and Progestin Receptors in Relation to Conventional Prognosis Indicators in Endometrial Carcinomas
Determination of hormonal dependency by biochemical estrogen (ERC) and progestin receptor (PRC) assays have been found clinically beneficial in breast carcinoma [1,2]. ERC and PRC assays are being used e.g. in selecting breast carcinoma patients suitable for endocrine therapy. In endometrial carcinoma the clinical significance of ERC and PRC has remained unclear, despite receptor determinations, since the early years of the seventies in several centres. As in breast cancer, ERC and PRC assays seem, however, to be able to discriminate hormone sensitive tumors from those which are not hormine dependent [1–4]. The preliminary data from trials with a limited number of patients and short follow-up time about ten years ago suggested that they are clinically useful markers of the aggressivity of endometrial malignancies [5–6]. At present, several clinical studies with a sufficient number of patients with ERC and/or PRC assays and long follow-up time have been accomplished [4,7–18]. By reviewing the data from these studies, the present article is aimed at describing the available knowledge of ERC and PRC as prognosis indicators in endometrial carcinoma.
Unable to display preview. Download preview PDF.
- 1.Vihko R, Alanko A, Isomaa V, Kauppila A: The predictive value of steroid hormone receptor analysis in breast, endometrial and ovarian cancer. Med Oncol & Tumor Pharmacother 3: 197–210, 1986Google Scholar
- 2.Desombre ER, Holt JA, Herbst AL: Steroid receptors in breast, uterine and ovarian malignancy. Diagnostic and therapeutic applications. In Gynecol Endocrinol, eds JJ Gold, JB Josimovich, Plenum Publishing Corporation, pp 511–528, 1987Google Scholar
- 6.Kauppila AJI, Isotalo H, Kujansuu E, Vihko R: Clinical significance of female sex steroid hormone receptors in endometrial carcinoma treated with conventional methods and medroxyprogesterone acetate. Excerpta Medica Intern Congr Series No 611. Proceedings of the International Symposium on Medroxyprogesterone acetate, pp 350–359, Excerpta Medica, Amsterdam, 1982Google Scholar
- 15.Kleine W, Bergmann W, Geyer H, Pfleiderer H: Progesteronreceptoren beim Endometriumkarzinoma - ein entscheidender Prognosefaktor. Arch Gynecol Obstet 245: 1–4, 1989Google Scholar